Pharma IPR Conference
February 15, 2024, 6:43 PM
Axinn is proud to be a Platinum Partner of the Pharma IPR Conference
- On March 5 at 11:00 AM, partners Aziz Burgy, Ted Mathias, and counsel Rebecca Clegg are excited to conduct a panel discussion covering “Polymorph Patents: Infringement and Invalidity Challenges.”
We Know Pharma … and They Know Us
Axinn is the go-to firm for IP matters of strategic importance and offers one of the leading pharmaceutical practices in the country. Our team combines its depth of substantive patent law and litigation experience with FDA and antitrust knowledge to offer clients a unique and holistic offering. Whether leading a patent trial on a blockbuster product or navigating the complex FDA regulatory regime, Axinn enables pharmaceutical clients to bring their products to market in the most profitable manner possible.
We've worked on some of the most successful products in the pharmaceutical industry representing over $30 billion in annual sales, including:

Extensive Pharmaceutical Industry Experience

Contact Us
Please reach out to any of our attorneys attending the conference. You can set up a time to meet with an individual attorney using the email link in their contact details.
Aziz Burgy Partner aburgy@axinn.com | Rebecca Clegg Counsel rclegg@axinn.com | ||
Ted Mathias Partner tmathias@axinn.com |

To subscribe to our publications, click here.
Tags
News & Insights
News & Insights
NJSBA Annual Meeting and Convention 2025
Speaking Engagement
Intellectual Property
CompLaw Antitrust West Coast Conference 2025
Speaking Engagement
Antitrust
AHLA Health Care Transactions Program 2025
Sponsorship
Antitrust
ACI 21st Annual Paragraph IV Conference
Speaking Engagement
Intellectual Property
ABA 73rd Annual Section of Antitrust Law Spring Meeting
Speaking Engagement
Antitrust
AIPLA CLE Web Series: Hot Topics in Chemical & Biotech Patent Practice
Speaking Engagement
17th Annual Practitioners' Think Tank on ITC Litigation & Enforcement
Speaking Engagement
Intellectual Property
Antitrust Enforcement Trends and Policies in 2025: Unfair Competition, Merger Policies, Premerger Procedures
Webinar
Antitrust
CompLaw Nordic 2025
Speaking Engagement
Antitrust
Compounding Problems: Recent Decisions on Tirzepatide Highlight Interplay Between FDA Anti-Compounding Enforcement and Private Intellectual Property Rights
Axinn Viewpoints
Intellectual Property